Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2025)
Top diagnostic & research stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best diagnostic & research stocks to buy now. Learn More.

Industry: Diagnostics & Research

Overview Zen Rating Price Value Growth Financials Momentum Sentiment

Diagnostics & Research is Zen Rated B and is the 48th ranked industry out of 145 stock market industries

Ticker	Company	Market Cap	Shares	Institutional %	Insider %	Net Insider (L12M)	Net Insider (L3M)
SHC	SOTERA HEALTH CO	$5.04B	284,093,929	80.22%	19.78%	Net Selling	Net Selling
IDXX	IDEXX LABORATORIES INC	$54.93B	79,851,330	90.09%	1.78%	Net Buying	Net Buying
A	AGILENT TECHNOLOGIES INC	$39.10B	283,498,871	88.44%	1.26%	Net Selling	Net Selling
DHR	DANAHER CORP	$162.91B	706,349,563	75.77%	24.23%	Net Selling	Net Selling
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	$10.00B	49,215,471	96.57%	3.43%	Net Buying	Net Buying
TMO	THERMO FISHER SCIENTIFIC INC	$219.82B	375,708,059	88.05%	0.91%	Net Buying	Net Buying
NEOG	NEOGEN CORP	$1.57B	217,298,626	98.02%	1.98%	Net Buying	Net Buying
IQV	IQVIA HOLDINGS INC	$38.61B	170,000,000	53.20%	46.80%	Net Selling	Net Buying
PRE	PRENETICS GLOBAL LTD	$226.22M	13,895,394	9.33%	0.00%
CDNA	CAREDX INC	$987.51M	51,432,639	77.88%	22.12%	Net Selling	Net Selling
QGEN	QIAGEN NV	$9.93B	217,685,000	77.09%	0.00%
BNR	BURNING ROCK BIOTECH LTD	$221.73M	107,741,467	1.32%	0.00%
ILMN	ILLUMINA INC	$20.55B	152,800,000	93.44%	6.56%	Net Selling	Net Selling
LH	LABCORP HOLDINGS INC	$20.97B	82,900,000	92.85%	1.52%	Net Selling	Net Selling
FLGT	FULGENT GENETICS INC	$822.27M	30,912,392	55.73%	41.68%	Net Selling	Net Selling
WAT	WATERS CORP	$22.93B	59,534,740	92.21%	7.79%	Net Selling	Net Buying
MEDP	MEDPACE HOLDINGS INC	$16.06B	28,168,223	26.85%	73.15%	Net Selling	Net Selling
CAI	CARIS LIFE SCIENCES INC	$7.89B	282,146,923	34.47%	65.53%	Net Selling	Net Buying
FONR	FONAR CORP	$96.55M	6,585,978	44.16%	3.58%
BLLN	BILLIONTOONE INC	$3.87B	45,768,760	0.04%	25.66%	Net Buying	Net Buying
DGX	QUEST DIAGNOSTICS INC	$19.53B	111,242,362	94.13%	1.77%	Net Selling	Net Selling
MYGN	MYRIAD GENETICS INC	$588.18M	93,213,722	91.13%	8.87%	Net Selling	Net Selling
MTD	METTLER TOLEDO INTERNATIONAL INC	$29.00B	20,428,445	95.44%	4.56%	Net Selling	Net Buying
ACRS	ACLARIS THERAPEUTICS INC	$326.12M	108,345,239	57.07%	42.93%	Net Selling
NEO	NEOGENOMICS INC	$1.59B	129,387,801	72.71%	27.29%	Net Buying	Net Selling
GH	GUARDANT HEALTH INC	$12.78B	126,041,089	66.41%	33.59%	Net Selling	Net Selling
ICLR	ICON PLC	$13.92B	76,359,932	97.40%	0.00%
CSTL	CASTLE BIOSCIENCES INC	$1.15B	29,188,659	85.72%	14.28%	Net Selling	Net Selling
XGN	EXAGEN INC	$135.53M	22,663,099	39.94%	49.06%	Net Selling	Net Selling
GRAL	GRAIL INC	$3.43B	38,982,223	63.66%	21.22%	Net Selling	Net Selling
RDNT	RADNET INC	$5.62B	77,146,342	70.67%	29.33%	Net Selling	Net Buying
BDSX	BIODESIX INC	$54.58M	7,955,685	3.49%	96.51%	Net Buying	Net Selling
RVTY	REVVITY INC	$11.01B	113,375,621	97.30%	2.70%	Net Selling	Net Selling
TWST	TWIST BIOSCIENCE CORP	$2.01B	61,148,026	88.44%	11.56%	Net Selling	Net Selling
MYNZ	MAINZ BIOMED NV	$4.95M	4,091,853	11.78%	0.00%
OPK	OPKO HEALTH INC	$990.33M	767,701,280	19.98%	80.02%	Net Buying	Net Buying
NTRA	NATERA INC	$31.92B	138,014,465	80.15%	19.85%	Net Selling	Net Selling
IMDX	INSIGHT MOLECULAR DIAGNOSTICS INC	$190.05M	28,664,437	16.58%	83.42%	Net Buying	Net Selling
NOTV	INOTIV INC	$18.01M	34,367,251	23.17%	39.38%	Net Selling	Net Buying
MDXH	MDXHEALTH SA	$16.58M	49,497,334	24.08%	75.92%
PSNL	PERSONALIS INC	$704.22M	88,804,348	64.17%	35.83%	Net Selling	Net Selling
STIM	NEURONETICS INC	$94.51M	68,485,922	30.87%	31.60%	Net Selling
NDRA	ENDRA LIFE SCIENCES INC	$5.62M	1,166,441	1.12%	96.17%	Net Buying	Net Buying
DRIO	DARIOHEALTH CORP	$71.00M	6,768,184	5.40%	94.60%	Net Buying
BIAF	BIOAFFINITY TECHNOLOGIES INC	$5.26M	4,498,709	5.91%	94.09%
LAB	STANDARD BIOTOOLS INC	$492.24M	384,565,414	54.36%	45.64%	Net Buying	Net Buying
PRPO	PRECIPIO INC	$40.61M	1,752,007	1.28%	98.72%	Net Buying	Net Buying
PRPH	PROPHASE LABS INC	$2.08M	4,617,902	22.42%	77.58%
SERA	SERA PROGNOSTICS INC	$126.20M	38,594,793	47.04%	25.17%	Net Selling	Net Selling
ISPC	ISPECIMEN INC	$3.33M	9,771,028	3.51%	66.08%
TRIB	TRINITY BIOTECH PLC	$15.14M	369,329,458	0.73%	0.00%
VNRX	VOLITIONRX LTD	$29.47M	122,801,572	21.27%	31.03%	Net Buying	Net Buying
EXAS	EXACT SCIENCES CORP	$19.31B	189,471,298	94.18%	3.30%	Net Selling	Net Selling
XWEL	XWELL INC	$3.29M	5,766,703	1.25%	98.75%
BNBX	BNB PLUS CORP	$9.60M	4,365,541	0.32%	99.68%
MBAI	CHECK-CAP LTD	$9.83M	5,850,906	0.60%	0.00%
ADVB	ADVANCED BIOMED INC	$7.23M	21,640,000	1.21%	0.00%

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Dec 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

1. Sotera Health Co (NASDAQ:SHC)

Sotera Health Co (NASDAQ:SHC) is the #1 top diagnostic & research stock out of 57 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Sotera Health Co (NASDAQ:SHC) is: Value: C, Growth: A, Momentum: C, Sentiment: C, Safety: B, Financials: B, and AI: C.

Sotera Health Co (NASDAQ:SHC) has a Due Diligence Score of 24, which is -2 points lower than the diagnostic & research industry average of 26. Although this number is below the industry average, our proven quant model rates SHC as a "A".

SHC passed 8 out of 33 due diligence checks and has weak fundamentals. Sotera Health Co has seen its stock return 32.86% over the past year, overperforming other diagnostic & research stocks by 15 percentage points.

Sotera Health Co has an average 1 year price target of $18.00, an upside of 1.41% from Sotera Health Co's current stock price of $17.75.

Sotera Health Co stock has a consensus Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Sotera Health Co, 25% have issued a Strong Buy rating, 25% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Idexx Laboratories (NASDAQ:IDXX)

Idexx Laboratories (NASDAQ:IDXX) is the #2 top diagnostic & research stock out of 57 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Idexx Laboratories (NASDAQ:IDXX) is: Value: C, Growth: C, Momentum: B, Sentiment: C, Safety: C, Financials: A, and AI: C.

Idexx Laboratories (NASDAQ:IDXX) has a Due Diligence Score of 50, which is 24 points higher than the diagnostic & research industry average of 26.

IDXX passed 17 out of 33 due diligence checks and has strong fundamentals. Idexx Laboratories has seen its stock return 66.66% over the past year, overperforming other diagnostic & research stocks by 49 percentage points.

Idexx Laboratories has an average 1 year price target of $751.25, an upside of 9.21% from Idexx Laboratories's current stock price of $687.89.

Idexx Laboratories stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Idexx Laboratories, 62.5% have issued a Strong Buy rating, 12.5% have issued a Buy, 25% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Agilent Technologies (NYSE:A)

Agilent Technologies (NYSE:A) is the #3 top diagnostic & research stock out of 57 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Agilent Technologies (NYSE:A) is: Value: B, Growth: C, Momentum: C, Sentiment: C, Safety: A, Financials: B, and AI: C.

Agilent Technologies (NYSE:A) has a Due Diligence Score of 46, which is 20 points higher than the diagnostic & research industry average of 26.

A passed 17 out of 38 due diligence checks and has strong fundamentals. Agilent Technologies has seen its stock return 2.61% over the past year, underperforming other diagnostic & research stocks by -15 percentage points.

Agilent Technologies has an average 1 year price target of $169.33, an upside of 22.77% from Agilent Technologies's current stock price of $137.93.

Agilent Technologies stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Agilent Technologies, 75% have issued a Strong Buy rating, 8.33% have issued a Buy, 16.67% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 6 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.37%, which is 1 percentage points higher than the diagnostic & research industry average of 0.69%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 27.2% indicates that its dividend yield is sustainable for the long-term.

2. Labcorp Holdings (NYSE:LH)

Labcorp Holdings (NYSE:LH) has an annual dividend yield of 1.14%, which is the same as the diagnostic & research industry average of 0.69%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 28.1% indicates that its dividend yield is sustainable for the long-term.

3. Danaher (NYSE:DHR)

Danaher (NYSE:DHR) has an annual dividend yield of 0.56%, which is the same as the diagnostic & research industry average of 0.69%. Danaher's dividend payout is not stable, having dropped more than 10% two times in the last 10 years. Danaher's dividend has shown consistent growth over the last 10 years.

Danaher's dividend payout ratio of 25.2% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -0.22% in the last day, and down -0.57% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are down.

What are the most undervalued diagnostic & research stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

1. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) is the most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Qiagen Nv has a valuation score of 29, which is 15 points higher than the diagnostic & research industry average of 14. It passed 2 out of 7 valuation due diligence checks.

Qiagen Nv's stock has gained 1.99% in the past year. It has underperformed other stocks in the diagnostic & research industry by -15 percentage points.

2. Fonar (NASDAQ:FONR)

Fonar (NASDAQ:FONR) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Fonar has a valuation score of 71, which is 57 points higher than the diagnostic & research industry average of 14. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has dropped -2.14% in the past year. It has underperformed other stocks in the diagnostic & research industry by -20 percentage points.

3. Revvity (NYSE:RVTY)

Revvity (NYSE:RVTY) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Revvity has a valuation score of 14, which is 0 points higher than the diagnostic & research industry average of 14. It passed 1 out of 7 valuation due diligence checks.

Revvity's stock has dropped -12.76% in the past year. It has underperformed other stocks in the diagnostic & research industry by -30 percentage points.

Are diagnostic & research stocks a good buy now?

53.49% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 7.26% over the next year.

2.17% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 26.09% of diagnostic & research stocks are rated B (Buy), 63.04% are rated C (Hold), 8.7% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 22.79x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.